Select your Background Color
add
add longest videos

Remoxipride (Roxiam) is an atypical antipsychotic which was previously used in Europe for the treatment of schizophrenia but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993. Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.



Read more...



This page contains text from Wikipedia, the Free Encyclopedia - http://en.wikipedia.org/wiki/Remoxipride

This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.









×